Condition
Acute Myeloid Leukemia Recurrent
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06152809Phase 1Recruiting
CIML NK Cells With Venetoclax for AML
NCT05735184Phase 1Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT04050280Phase 2Recruiting
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
NCT05574608Early Phase 1Unknown
Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Showing all 4 trials